Section I: Oncology
1. Adrenocortical Cancer
2. Anal Cancer
3. Gallbladder Cancer and Cholangiocarcinoma
4. Bladder Cancer
5. Brain Cancer
6. Breast Cancer
7. Carcinoid Tumors
8. Carcinoma of Unknown Primary
9. Cervical Cancer
10. Colorectal Cancer
11. Endometrial Cancer
12. Esophageal Cancer
13. Gastric Cancer
14. Gestational Trophoblastic Neoplasia
15. Head and Neck Cancers
16. Hepatocellular Carcinoma
17. HIV-Related Malignancies
18. Leukemia, Acute Lymphoblastic (Adult)
19. Leukemia, Acute Myelogenous
20. Leukemia, Chronic Lymphocytic
21. Leukemia, Chronic Myelogenous
22. Leukemia, Hairy Cell
23. Lung Cancer
24. Lymphoma, Hodgkin's
25. Lymphoma, Non-Hodgkin's
26. Melanoma
27. Mesothelioma
28. Multiple Myeloma
29. Ovarian Cancer
30. Pancreatic Cancer
31. Pheochromocytoma
32. Prostate Cancer
33. Renal Cell Carcinoma
34. Sarcomas
35. Testicular Cancer
36. Thymic Carcinoma
37. Thyroid Cancer
38. Vaginal Cancer
Section II: Supportive Care, Drug Preparation, Complications, and Screening
39. Chemotherapy-Induced Nausea and Vomiting: Prophylaxis and Treatment
40 Drug Preparation and Administration
41 Chemotherapy Dose Modifications
42 Antineoplastic Drugs: Preventing and Managing Extravasation
43 Growth Factors
44 Clinical Indications for Bisphosphonates in a Hematology-Oncology Setting
45 Transfusion Therapy
46 Oncologic Emergencies
47 Fever and Neutropenia
48 Managing and Preventing Catheter-Related Bloodstream Infections
49 Venous Catheter-Related Thrombosis
50 Complications and Follow-up After Hematopoietic Stem Cell Transplantation
51 Radiation Complications
52 Cancer Pain: Assessment and Management
53 Hospice Care and End-of-Life Issues
54 Cancer Screening
55 Genetics of Common Inherited Cancer Syndromes
Section III: Selected Hematologic Diseases
56 Von Willebrand Disease
57 Hemophilia
58 The Hypercoagulable State
59 Heparin-Induced Thrombocytopenia (HITT) and HITT With Thromboembolic Syndrome
60 Autoimmune Hemolytic Anemia
61 Sickle Cell Disease: Acute Complications
62 Aplastic Anemia
63 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS)
64 Idiopathic Thrombocytopenic Purpura
65 Polycythemia Vera
66 Essential Thrombocythemia
67 Myelodysplastic Syndromes
Index
-Introduction-
Timely: nearly all training fellow are double boarding in hematology and oncology and require such a reference
Includes all practice guideline recommendations from the National Cancer Institute, American Society of Clinical Oncology, and American Society of Hematology
Applicable to daily practice -- includes precise drug dosages and combinations for tailoring multi-drug regiments
-Key Features-
FEATURE: Very clinically oriented and prescriptive. BENEFIT: All about precise drug dosages and potential combinations for tailoring multi-drug regimens -- immediately applicable to daily practice.
FEATURE: First book to bridge the disciplines of hematolgy and oncology in a practical and clinical way. BENEFIT: Synthesizes these two areas into a cohesive whole. Nearly all training fellows are now double boarding in hematology and oncology.
FEATURE: Imbued with National Cancer Institute strategies and philosophy for disease management. BENEFIT: Reflects the authority of one of the world¢¯s leading centers for education, research, and treatment.
FEATURE: Includes all practice guideline recommendations from the National Cancer Institute, American Society of Clinical Oncology, and American Society of Hematology. BENEFIT: An important summation of state-of-the-art practice guidleines from the leading organizations
-Author Biography-
Michael M. Boyiadzis, MD, MHSc Assistant Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Peter F. Lebowitz, MD, PhD Assistant Professor of Medicine, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC
James N. Frame, MD, FACP Clinical Associate Professor, Robert C. Byrd Health Sciences Center of West Virginia University School of Medicine, Charleston Division; and Medical Director, David Lee Outpatient Cancer Center, Charleston Area Medical Center Health Systems, Inc., Charleston, West Virginia
Tito Fojo, MD, PhD Senior Investigator, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland